Wendy's rejects Peltz's $1.4B bid, adopts poison pill to defend turnaround plan

Wendy's board unanimously rejected a $1.4 billion all-cash takeover proposal from an investor group led by Nelson Peltz, deeming the offer undervalued. The company simultaneously activated a one-year 'poison pill' defense to deter hostile acquisitions. While the chain reported its seventh consecutive quarter of declining same-store sales, it exceeded Wall Street earnings expectations, with CEO Bob Wright citing a successful turnaround strategy.
Key points
- Wendy's independent directors rejected the $7.35 per share cash offer from Trian Fund Management, BlueFive Capital, Sixth Street Partners, and Flynn Group, stating it 'substantially undervalues' the company.
- The company adopted a shareholder rights plan, or 'poison pill,' which triggers if any entity acquires 15% or more of Wendy's shares, lasting for one year.
- Wendy's reported third-quarter adjusted earnings per share of $0.13, beating estimates, and revenue of $547 million, despite a 5.7% decline in US same-store sales.
- CEO Bob Wright emphasized the 'Dave's Way' turnaround strategy, which includes improving food quality with thicker bacon and whole-leaf lettuce, and closing underperforming locations.
- The investor group previously rejected a standstill agreement proposed by Wendy's, prompting the board to implement the defensive measure.
Background
This dispute marks the latest chapter in a long-standing relationship between Nelson Peltz and Wendy's. Peltz previously owned the chain through his company Triarc in 2008 and served on the board for 17 years before becoming chairman emeritus in 2024. The current conflict follows a period of financial strain for the chain, including the bankruptcy of major franchisee Meritage Hospitality Group in September and a decline in US burger market share from 11.5% in 2019 to 10.4% last year.
How outlets are covering it
ABC News and CNBC focused on the board's rejection of the bid and the activation of the poison pill, highlighting the company's confidence in its turnaround strategy. Yahoo Finance emphasized the specific operational changes under the 'Dave's Way' plan, such as menu improvements, and noted that while earnings beat expectations, same-store sales continued to decline. All sources agreed that the offer was viewed as undervaluing the company's long-term potential, though CNBC noted the stock had lost about 60% of its value over the last three years.
Why it matters
The rejection of the buyout and adoption of the poison pill signal Wendy's commitment to its independent turnaround strategy despite ongoing sales declines. The outcome will determine whether the company can successfully execute its operational improvements or if activist investors will pursue further hostile acquisition attempts in the future.
What to watch
Wendy's will continue to implement its 'Dave's Way' turnaround plan, including menu changes and location closures. The company plans to acquire up to 163 restaurants from the bankrupt Meritage Hospitality Group. The poison pill will remain in effect for one year, potentially deterring further takeover attempts unless the board agrees to a standstill agreement.
- Wendy's rejects buyout bid from activist investor and adopts 'poison pill' plan ABC News - Breaking News, Latest News and Videos
- Wendy's turned down Nelson Peltz's $1.4 billion offer. It's betting instead on thicker bacon and whole-leaf lettuce. Yahoo Finance
- Wendy's rejects $1.4 billion takeover proposal from Nelson Peltz’s Trian CNBC
- Wendy's rejects Trian-led $1.4 billion buyout offer, adopts 'poison pill' plan Reuters
- Wendy’s Rejects Trian’s $1.4 Billion Takeover Offer WSJ
Want the full story? Read the original reporting
Read on ABC News - Breaking News, Latest News and Videos